Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

2020

Baden, 2021, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N. Engl. J. Med., 384, 403, 10.1056/NEJMoa2035389

Baum, 2020, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science, 369, 1014, 10.1126/science.abd0831

Cantuti-Castelvetri, 2020, Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity, Science, 370, 856, 10.1126/science.abd2985

Cele, 2021, Escape of SARS-CoV-2 501Y.V2 Variants from Neutralization by Convalescent Plasma, medRxiv

Cohen, 2021

Craven, 2021

Crawford, 2020, Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays, Viruses, 12, E513, 10.3390/v12050513

Faria, 2021

Galloway, 2021, Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021, MMWR Morb. Mortal. Wkly. Rep., 70, 95, 10.15585/mmwr.mm7003e2

Garcia-Beltran, 2021, COVID-19-neutralizing antibodies predict disease severity and survival, Cell, 184, 476, 10.1016/j.cell.2020.12.015

Greaney, 2021, Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition, Cell Host Microbe, 29, 44, 10.1016/j.chom.2020.11.007

Greaney, 2021, Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe, 29, 463, 10.1016/j.chom.2021.02.003

Herper, 2021

Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052

Hou, 2020, SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo, Science, 370, 1464, 10.1126/science.abe8499

Hu, 2021, Emerging SARS-CoV-2 Variants Reduce Neutralization Sensitivity to Convalescent Sera and Monoclonal Antibodies, bioRxiv

Jangra, 2021, The E484K Mutation in the SARS-CoV-2 Spike Protein Reduces but Does Not Abolish Neutralizing Activity of Human Convalescent and Post-Vaccination Sera, medRxiv

Jones, 2021

Ju, 2020, Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 584, 115, 10.1038/s41586-020-2380-z

Korber, 2020, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell, 182, 812, 10.1016/j.cell.2020.06.043

Le Bert, 2020, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature, 584, 457, 10.1038/s41586-020-2550-z

Legros, 2021, A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity, Cell. Mol. Immunol., 18, 318, 10.1038/s41423-020-00588-2

Lemieux, 2020, Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events, Science, 371, eabe3261, 10.1126/science.abe3261

Liu, 2021, The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2, bioRxiv

Moore, 2004, Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2, J. Virol., 78, 10628, 10.1128/JVI.78.19.10628-10635.2004

Muik, 2021, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera, Science, 10.1126/science.abg6105

Naveca, 2021

2021

Oude Munnink, 2021, Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans, Science, 371, 172, 10.1126/science.abe5901

Oxner, 2020

Paiva, 2020, Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil, Viruses, 12, E1414, 10.3390/v12121414

Pinto, 2020, Structural and Functional Analysis of a Potent Sarbecovirus Neutralizing Antibody, bioRxiv

Plante, 2020, Spike mutation D614G alters SARS-CoV-2 fitness, Nature

Polack, 2020, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med., 383, 2603, 10.1056/NEJMoa2034577

Rees-Spear, 2021, The Impact of Spike Mutations on SARS-CoV-2 Neutralization, bioRxiv

Resende, 2021

Riepler, 2020, Comparison of Four SARS-CoV-2 Neutralization Assays, Vaccines (Basel), 9, 13, 10.3390/vaccines9010013

Santos, 2021, The High Infectivity of SARS-CoV-2 B.1.1.7 Is Associated with Increased Interaction Force between Spike-ACE2 Caused by the Viral N501Y Mutation, bioRxiv

Shen, 2021, SARS-CoV-2 Variant B.1.1.7 Is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines, bioRxiv

Siebring-van Olst, 2013, Affordable luciferase reporter assay for cell-based high-throughput screening, J. Biomol. Screen., 18, 453, 10.1177/1087057112465184

Skelly, 2021, Vaccine-Induced Immunity Provides More Robust Heterotypic Immunity than Natural Infection to Emerging SARS-CoV-2 Variants of Concern, Research Square

Tegally, 2021, Sixteen novel lineages of SARS-CoV-2 in South Africa, Nat. Med., 10.1038/s41591-021-01255-3

Vasques Nonaka, 2021, Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in Brazil, Preprints

Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, 10.1038/s41467-020-16256-y

Wang, 2021, Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization, bioRxiv

Wibmer, 2021, SARS-CoV-2 501Y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma, bioRxiv

Wu, 2021, mRNA-1273 Vaccine Induces Neutralizing Antibodies against Spike Mutants from Global SARS-CoV-2 Variants, bioRxiv

Yang, 2020, Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro, Biosafety and Health, 2, 226, 10.1016/j.bsheal.2020.08.004

Yurkovetskiy, 2020, Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant, Cell, 183, 739, 10.1016/j.cell.2020.09.032

Yurkovetskiy, 2020, Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant, Cell, 183, 739, 10.1016/j.cell.2020.09.032

Zhou, 2020, SARS-CoV-2 Spike D614G Variant Confers Enhanced Replication and Transmissibility, bioRxiv